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SUMMARY: 
Pulmonary arteriovenous malformations (PAVMs) are vascular structures that provide a 
direct capillary-free communication between the pulmonary and systemic circulations. 
The majority of patients have no PAVM-related symptoms, but are at risk of major 
complications that can be prevented by appropriate interventions. More than 90% of 
PAVMs occur as part of hereditary haemorrhagic telangiectasia (HHT), the genetic 
condition most commonly recognised by nosebleeds, anaemia due to chronic 
haemorrhage, and/or the presence of arteriovenous malformations in pulmonary, hepatic 
or cerebral circulations. Patients with HHT are also at higher risk of pulmonary 
hypertension and pulmonary embolic disease, management of which can be compounded 
by other aspects of their HHT.  
 
This chapter primarily addresses PAVMs and pulmonary HHT in the clinical setting, in 
order to improve patient care. Clinical presentation patterns, diagnostic strategies and 
management options are presented in detail. Relevant pathophysiological mechanisms 
discussed include new topics for the PAVM literature, such as the alveolar transit of 
venous bubbles during diving and contrast echocardiography. 
 
 
 
INTRODUCTION 
Pulmonary arteriovenous malformations (PAVMs) are abnormal vascular structures that 
provide a direct capillary-free communication between the pulmonary and systemic 
circulations 1. Pulmonary arterial blood passing through these right-to-left (R-L) shunts 
cannot be oxygenated, leading to hypoxaemia; the fragile wall of the PAVM sac may 
rupture 2,   and the absence of a filtering capillary bed allows particulate matter to reach the 
systemic circulation resulting in embolic cerebrovascular accidents (CVA) and cerebral 
abscesses.  PAVMs are particularly dangerous during pregnancy and other stresses such as 
diving. Complications can be limited if the condition is identified and treated, yet until 
recently, the importance of treatment for PAVMs has been poorly recognised by respiratory 
physicians (Figure 1). 
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The majority of pulmonary AVMs ([94%] in the study by Shovlin et al.3) occur as part of 
hereditary haemorrhagic telangiectasia (HHT).  HHT is most commonly recognised by 
nosebleeds (epistaxis) and anaemia due to telangiectasia in the nose and gastrointestinal 
tract.  Arteriovenous malformations (AVMs occur not only in the pulmonary circulation, but 
also in mucocutaneous 4, hepatic 5, gastrointestinal 6, and cerebrospinal 7, 8 vascular beds.  
Additionally, patients with HHT are at higher risk of pulmonary hypertension 9, and 
pulmonary embolic disease 10, management of which can be compounded by other aspects 
of their HHT.  
 
Most patients with PAVMs and HHT are unaware they have HHT when their PAVMs are 
diagnosed: in the study by Shovlin et al.3, 121 (59%) out of 205 were unaware. It is 
therefore crucial that the respiratory physician is alert to the possibility of HHT in the 
PAVM patient; aware that mucocutaneous telangiectasia are often subtle (Figure 2); and 
recognizes that the majority of patients will not volunteer a personal or family history of 
HHT or nosebleeds, unless specifically asked and allowed time to check with relatives.  
 
OVERVIEW OF HHT 
HHT is generally quoted as affecting 1 in 5-8,000, with precise prevalence figures for 
specific regions in Europe 14, 15, the West Indies (Dutch Antilles) 16, and Japan 17.  
 
Current clinical diagnostic criteria for a definitive diagnosis of HHT require the presence of 
three out of four key features, namely 1) spontaneous recurrent epistaxis (nosebleeds), 2) 
telangiectases at characteristic sites, 3) a visceral manifestation (such as PAVMs), and 4) an 
affected first degree relative 18.  An individual has a diagnosis of “definite HHT” if three 
Figure 1:  Delays between PAVM 
diagnosis and treatment according 
to type of presentation in 219 
consecutive patients. Reproduced 
from Thorax 3 with permission 
from the publisher. 
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criteria are present; “suspected HHT” if two are present, and “unlikely HHT” if only one is 
present 18.  For patients with definite clinical HHT, identification of a causative gene 
mutation is not required to ‘confirm’ their diagnosis, and at present, does not modify 
recommended management.  HHT disease-causing mutations are not found in approximately 
15-20% of HHT families 19-21: this should not affect a clinical diagnosis of HHT made for 
individuals within such families. 
 
 
 
 
 
 
 
 
 
 
Genetics of HHT 
HHT is inherited as an autosomal dominant trait. Three disease genes have been identified.  
HHT type 1 is caused by mutations in ENG encoding endoglin 22, and HHT type 2 by 
mutations in ACVRL1 encoding activin receptor like kinase (ALK1) 23, and mutations in 
MADH4 cause HHT in association with juvenile polyposis (JPHT) 24. There are at least two 
further unidentified genes that can cause classical HHT, HHT3 on chromosome 5q 25, 26, and 
HHT4 on chromosome 7p 27.  The genes mutated in HHT encode endothelial cell-expressed 
proteins that mediate signalling by the TGF-ß superfamily (Figure 3).   
Figure 2:  Relative importance of nosebleeds and telangiectasia in making a 
clinical diagnosis of HHT.  In the series of female PAVM patients reported by Shovlin 
et al. 11, the presence of telangiectasia at HHT diagnostic site (lips, internal oral mucosa 
and tongue, finger tip pads) was recorded at the time of assessment and subsequently 
classified into 4 categories. A) Illustration of typical (3 or more, readily detectable by 
careful inspection of the sites) compared to florid (as illustrated by Shovlin et al 12 and 
Faughnan et al 13); sparse, or absent.    B). Proportions of women demonstrating the 
clinical features at the age of ≤30ys, and ≤ 45ys.  Note that “classical tel.” referred to 
three or more in classical sites (as in a), or more florid. Contrast the high proportions of 
women that did not demonstrate such telangiectasia with the high proportions who 
declared a family history of nosebleeds (and/or HHT) when prompted.    
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Figure 3: Transforming growth factor (TGF)-ß signalling pathways relevant to 
pulmonary arteriovenous malformations (PAVMs) and/or hereditary 
haemorrhagic telangiectasia (HHT). Protein products of mutated genes are boxed in 
solid lines (HHT/PAVMs) or dotted lines (pulmonary arterial hypertension). BMP: bone 
morphogenetic protein; GDF: growth and differentiation factor; ActR: activin receptor; 
T ß R: TGF- ß receptor; BMPR: BMP receptor; ALK: activin receptor-like kinase. 
Reproduced from25, with permission from the publisher. 
 
 
 
More than 500 different ENG and ACVRL1 mutations have been reported to the HHT 
Mutation Database at www.hhtmut.org to date, with no common mutations 28.  A body of 
evidence indicates that HHT mutations result in a non functional allele. Many cannot 
generate a mutated protein, most obviously entire gene deletions 29; start codon mutations 30 
, and mutations with no detectable mutant RNA 31 30, 32.  For endoglin, expression of ~50% 
of normal is observed in a variety of cells from HHT1 patients 33-37 38, with endogenous 
mutated endoglin protein species either not detected, or retained intracellularly at low levels 
33, 34, 37. For ALK1, where missense mutations are more common, in vitro generated mutated 
proteins display defective signalling. 39 Although there have been suggestions that the 
telangiectasia/AVMs may develop at sites in which there was a genetic ‘second hit’ 40, it is 
believed that in most if not all cases, HHT results from haploinsufficiency, that is lack of 
sufficient protein for normal function  
 
Development of HHT telangiectasia 
In man, computer reconstruction of serial sections suggest that the smallest HHT cutaneous 
telangiectatic lesion is  a focal dilatation of the post capillary venule which enlarges, 
connects with dilated arterioles with loss of the intervening capillary bed, and form 
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arteriovenous communications 41. The development of de novo AVMs can be observed in 
murine HHT models 42.  In contrast to normal veins exposed to arterial pressures 43, the 
vessels immediately beyond the new arteriovenous communication do not arterialise 44, and 
wall thickness remains low compared to the lumen radius 45 (Fig 3B), with disorganised  
wall structures 11, 46-48.     
 
Since most vessels within HHT-affected vascular beds develop and function normally, 
endoglin or ALK-1 haploinsufficiency must be deleterious in particular contexts.  As 
discussed elsewhere 44, transgenic models of HHT 42, 49-51 are focussing attention on aberrant 
vascular responses to injury-induced angiogenic stimuli, when the mutated genes in HHT 
result in the inability of a blood vessel to mature appropriately 42, 50, 51.  Murine models also 
provide mechanistic insights into vascular bed specificity of HHT vessel formation, with 
evidence, for murine endoglin and ALK-1, of differential basal expression levels 52; dynamic 
down-regulation in inflammation 53, 54; different requirements for angiogenesis; 42 and 
differential generation of  reactive oxygen species provoking vascular injury 49, 55 . 
 
Which ligand is important in the pathogenesis of the HHT vascular lesions remains the 
subject of intense debate and study.  Many recent data focus on a defective response to TGF-
ß1 signalling, as impaired recruitment of mural cells to vessels 56, 57 may be mediated at least 
in part via reduced endothelial cell secretion of TGF-ß1 58, 59 and/or reduced TGF-ß1 
induced responses. 56, 58.   Other models suggest that BMP9 may be the ligand most 
implicated in HHT pathogenesis 60-62.  The association of endoglin with the eNOS/hsp 90 
complex leading to uncoupling of eNOS activity in Eng+/- mice 55 may also be crucial in 
HHT pathogenesis.  
 
 
Clinical consequences of telangiectasia and AVMs 
Fragile-walled nasal telangiectasia are responsible for the nosebleeds (epistaxis) that affect 
the majority of patients at some point in their lives, often sufficiently frequently to require 
ENT attention and long term maintenance iron or transfusions. Gastrointestinal 
telangiectasia, present in a smaller proportion of individuals, also bleed, and may contribute 
to chronic blood loss.  Both gastrointestinal and mucocutaneous telangiectasia become more 
prevalent with age 4, 44, 63. Telangiectasia also occur in other HHT-affected vascular beds, 
where they are usually silent, and overshadowed by the consequences of larger 
arteriovenous malformations.   
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For larger arteriovenous malformations in HHT, bleeding is less common, particularly in the 
pulmonary circulation where AVMs are normally perfused at much lower pressures.  Instead 
the consequences of AVMs tend to result from inappropriate shunting of blood past the 
relevant capillary beds, resulting in right-to-left (R-L) shunting for PAVMs;  left-to-right 
shunting for systemic AVMs; and hepato-portal shunting for certain hepatic AVMs.   Both 
right-to-left, and left-to-right shunting result in compensatory increases in cardiac output, 
increases that are generally well tolerated prior to advancing age or concomitant pathologies, 
particularly the onset of iron deficiency anaemia, or atrial fibrillation. 
 
Other pathologies in HHT 
Pulmonary emboli and deep venous thromboses  
HHT patients are not protected from prothrombotic risks 10, and when pulmonary emboli 
occur, they may temporarily occlude pulmonary AVMs 64, 65 and/or lead to paradoxical 
emboli 65. Deep venous thromboses and  pulmonary emboli affected 6-7% of two separate 
European HHT populations 10, 66, associated in one series with elevated plasma levels of 
coagulation factor VIII (FVIII) 10,  one of the strongest predictors of recurrent venous 
thromboembolic events in the general population 67, 68,  and also associated with chronic 
thromboembolic pulmonary hypertension 69-71.  The recent demonstrations that the 
pulmonary endothelium synthesizes FVIII 72, 73  provides a rationale for why FVIII levels 
may be higher in HHT patients, but mechanistic data are awaited.   
 
Other respiratory pathologies: 
HHT-specific pathologies occur in individuals who may have other respiratory diseases.  
The natural history of these conditions does not appear to differ in HHT (Shovlin, personal 
observation).  
 
 
The remainder of this article will focus primarily on pulmonary AVMs.  For further details 
on other aspects of HHT, the reader is referred to International Guidelines based on 
systematic assessments of HHT publications up to October 2006 74, and review articles 
incorporating the 2006-2010 evidence base 13, 44, 75, 76. 
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PULMONARY AVMs 
Anatomy and development 
PAVMs affect approximately 50% of HHT patients 77, with prevalence depending on the 
genotype. Macroscopic PAVMs are more prevalent in HHT1 than HHT2 21, 78-82, and in one 
recent study, 85% of 92 HHT1 patients had evidence of intrapulmonary R-L shunting 
compared to 36% of 97 HHT2 patients 83. 
 
PAVMs range in size from telangiectases 46 to large ‘classical’ lesions with hypertrophied 
feeding arteries, aneurysmal venous sacs and dilated draining veins 84. (Figure 4A)   
Approximately 70% are basally-situated 85-88. In HHT, pulmonary AVMs are usually 
multiple 3. Diffuse PAVMs have been defined as multiple small PAVMs affecting every 
segment of one or more lobes 89 or a single segment 90 (Figure 4B). 
 
Figure 4: 
 
 
Figure 4.  Pulmonary 
arteriovenous malformations  
(PAVMs). A) Pulmonary 
angiogram of a right basal 
PAVM with two dominant 
feeding vessels before (a,b) and 
after (c,d) embolisation with 
Amplatzer vascular plugs (AGA 
Medical Corporation, Plymouth, 
MN, USA). The patient was 
diagnosed by family screening, 
but had had a stroke previously. 
B) Computed tomography (a) 
and pulmonary angiogram (b) 
showing a diffuse PAVM in the 
anterior segment of the left 
upper lobe. The PAVM had 
been diagnosed following 
presentation with a cerebral 
abscess: post-embolisation, the 
arterial oxygen saturation 
increased from 89% supine, 
91% erect to 93% supine, 95% 
erect with symptomatic 
improvement. 
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PAVMs can develop in the pre or perinatal period 12, and recent data highlight that PAVMs 
can be detected in childhood 91, 92.  There are few data available regarding growth of PAVMs 
once present, but proven times of growth include puberty, pregnancy, and pulmonary venous 
hypertension 93-97.  Spontaneous regression 98 most likely reflects auto-embolization by a 
pulmonary embolus, as described in a recent case report where spontaneous recanalisation 
subsequently occurred 65. 
 
Physiology 
Right to left (R-L) Shunt  
In normal individuals, the anatomical R–L shunt is less than 2% of the cardiac output, 
ascribed to the post-pulmonary drainage of bronchial veins into the pulmonary veins and 
thebesian vessels into the left atrium.  In patients with PAVMs, the shunt fraction 
(proportion of the cardiac output using the shunt pathways) varies, tending to be higher  in 
earlier series where patients were more often symptomatic88,99-103 than in later series. 3,104,105  
 
Confirmation that the R–L shunt is the predominant cause of the arterial hypoxaemia in 
PAVM patients comes from three sources.  There is an inverse relationship between the R–L 
shunt fraction and arterial PO2 /SaO2 106;  calculations from SaO2 breathing air, are in good 
agreement with measurements of the anatomic R-L shunt 100; and temporary occlusion of 
PAVMs (by an occluding balloon 104, or  pulmonary emboli 65) demonstrated transient 18-
20% increases in SaO2 65,104.  In occasional patients with significant coexisting lung disease, 
ventilation–perfusion mismatching may also contribute to hypoxaemia.   
 
Pulmonary haemodynamics.  
The pulmonary vascular resistance (PVR) of PAVMs is less than that of the surrounding 
normal lung due to the absence of a microvascular bed 99. The effect on the overall PVR 
depends on the proportion of the cardiac output flowing through the shunt channels. 
Reduction in PVR in the apparently uninvolved lung 99 most likely reflects the presence of 
undetected microvascular PAVMs in the apparently normal lung, though there may also be 
significant vasodilatory stimuli 107.  The overall Ppa mean is usually low to low-normal 
99,104, 105, 108 reflecting the high total pulmonary blood flow. 
 
Pulmonary Function  
Sprirometric values are usually normal, 88, 104 but vital capacity may be reduced in the 
presence of very large PAVMs 103.   DLCO and KCO values less than 70% are unusual, and 
often signify the presence of widespread small vascular malformations.  However, low 
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DLCO/ KCO values are also found in patients with large R-L shunts 88, 102, 103, when a 
vascular steal through the low resistance PAVMs contributes to the low diffusion values 104, 
and improvement may be observed post embolization 104.  
 
Posture  
As the majority of PAVMs are at the lung bases 47, 85-88, a frequent finding is orthodeoxia 88, 
100, 101, 104, 106 due to a gravity-induced increase in right-to-left shunting on standing 100.  In a 
recent series of 155 consecutive untreated patients with CT-proven PAVMs, 51 (32.9%) 
demonstrated an SaO2 fall of ≥2% in replicate measurements averaged over 4 minutes after 
standing for 7-10 minutes, compared to the equivalent average supine reading (Santhirapala 
et al, manuscript in preparation).  A smaller fall of 1-2% was present in a further 28 (18%) 
of patients. (Santhirapala et al, manuscript in preparation).   
 
Exercise 
In the healthy lung, PVR falls on exercise to half its value at rest, because of dilation and 
recruitment of vessels in the pulmonary capillary bed. The effects of exercise on SaO2 in a 
PAVM-affected patient depends on the change in vascular resistance through the shunt 
channels in relation to the change in the resistance of the normal vessels  99 101 (see 109 for 
further discussion).   Overall, work capacity is well preserved in PAVM patients, even when 
SaO2 on exercise is <80% 99,104,106.  Recent studies of 88 patients with CT-proven pulmonary 
AVMs demonstrated little effect of SaO2 on dyspnoea grade, once age-adjusted. 110   
 
Pregnancy  
In normal pregnancy, complex physiological vasodilatory responses are associated with the 
increase in cardiac output that approaches 50% in the third trimester 111. Cardiac chamber 111 
and aortic 112 dimensions increase in normal pregnancies.  The rise in cardiac output is 
associated with a fall in PVR, with one study demonstrating PVR values to be 33% lower in 
11 healthy women at 16 weeks of pregnancy compared to 15 non-pregnant controls, with 
mean Ppa in the groups of 10 and 13 mm Hg respectively 113.   
 
For pregnant PAVM patients, the PAVMs may enlarge 94, 96, 97, 114, 115.  At such times, a fall 
in arterial PaO2/SaO2 may be masked 116, due to the increase in mixed venous oxygenation 
resulting from progesterone-stimulated increased minute ventilation (VdotE) 117, 118.  Sudden 
falls in post partum SaO2, mimicking the presentation of an acute pulmonary embolus, are 
reported 116.   
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Diving 
During diving, the increased barometric pressures leads to gases dissolving in the tissues on 
descent. Bubbles liberated from supersaturated tissues on ascent cause decompression illness 
(DCI) if they are not removed by the alveolar capillary filter.  Cardiac 119, 120 and pulmonary 
R-L shunts121, 122  are associated with an increased risk of DCI in divers, by allowing 
paradoxical gas embolism, leading to vascular obstruction and resultant tissue ischaemia.  
DCI does not occur after bubble contrast echocardiography in people with a R-L shunt, 
because the gas in a small number of bubble emboli passes down the concentration gradient 
into the tissues, and the bubble emboli dissolve. After a dive however, tissues are 
supersaturated with dissolved nitrogen, and bubble emboli are amplified as nitrogen passes 
from the supersaturated tissues into the bubbles.  
 
The risk of DCI is dependent on the characteristics of the dive which determines the number 
of venous bubbles liberated and the amount of dissolved nitrogen in tissues that is available 
to amplify embolic bubbles.  However, many individuals experiencing decompression 
illnesses are affected after dives with acceptable profiles, when it is believed that the R-L 
shunt allows venous bubbles that form during decompression after many innocuous dives to 
bypass the alveolar capillary filter.  The risk of decompression illness is also affected by the 
size of the shunt, with the majority of episodes of decompression illness occurring in a small 
minority of the population who have the largest right to left shunts 121, 122. 
 
Flying 
There are theoretical concerns that the reduced barometric pressure and relative immobility 
associated with flying might exacerbate hypoxaemia and risks of venous thromboembolism 
for PAVM patients, particularly as many asymptomatic patients with PAVMs have SaO2 
lower than the cut off recommended for flying 123.  A recent retrospective questionnaire-
based study examined the frequency of flight-related complications in 3,950 flights in 145 
HHT patients, 95 [65%] of whom had PAVMs 124.  111 (77%) patients reported no 
complications during or after flights. There was no difference in erect SaO2 at sea level 
between the six (4%) who reported dyspnoea, and those who did not 124. 
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Clinical presentation patterns 
Respiratory Symptoms  
Dyspnoea is the respiratory symptom most commonly reported by PAVM patients, but may 
not be appreciated until after the condition has been treated.  PAVMs generally result in 
symptomatic dyspnoea only when resting arterial oxygen saturations are below 80% 3,108, 
and  in a study of 88 patients with CT-proven pulmonary AVMs, no PAVM patients had an 
MRC dyspnoea grade 126 of higher than two, unless there was major concomitant pathology 
110.  
 
Haemorrhage leading to haemoptysis or haemothorax is a relatively rare feature of PAVMs, 
with three important exceptions: (1) during pregnancy (discussed below); (2) in association 
with pulmonary hypertension 127, and (3), in the presence of spontaneous or post-
embolization 90, 128 systemic arterial blood supply to PAVM sacs.  
 
PAVMs do not usually cause chest pain.  Reported series that pleuritic chest pains are 
present in up to 10% of PAVM patients (Table 1) most likely reflect ascertainment bias, 
following CTPA investigation of patients for suspected pulmonary embolism.  
 
Neurological features  
Ischaemic strokes and cerebral abscess are reported in high proportions of PAVM patients, 
attributed to paradoxical emboli through PAVMs 87 104 135 140.  In one series of 219 
consecutive PAVM patients, corrected for ascertainment bias, 9% of patients had a cerebral 
abscess and 11.3% an ischemic stroke, with  relative risks particularly high in young adults 3.  
Anderson Gill extension of Cox proportional hazards models indicated no clear relationship 
between the risk of ischemic stroke or cerebral abscess with any of six markers of PAVM 
severity 3, or with conventional neurovascular risk factors. There were strong association 
between ischaemic stroke and low Ppa mean, and between cerebral abscess, male gender and 
dental microrganisms 3.  The prevalence of migraine with aura is considerably increased in 
individuals with any form of right-to-left shunt, and thefrequency of migraine for PAVM 
patients is approximately doubled compared to general population data, general population 
controls, or HHT patients without PAVMs 138, 139, 141.    
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Table 1 : Clinical features of untreated PAVMs     
                     Published series    
   mean  % range  N 
 
Respiratory 
Asymptomatic  49  25-58  260 
 
Dyspnea  50   27-71  685 
Chest pain  12  6-18  390 
Haemoptysis  11  4-18  671 
Haemothorax  1  0-2  258 
 
Cyanosis  27  9-73  467 
Clubbing  28  6-68  459 
Bruit   31  3-58  455 
 
Embolic phenomenon   
Cerebral abscess 12.9  0-25  635 
CVA/TIA    27  11-55  401   
CVA   13.7  9.5-18  262 
TIA         22.1  6.3-36  262      
Migraine  44.7  38-57  266 
 
Table 1: Clinical features of untreated PAVMs    Data derived from figures in 
references 47, 85-88, 98, 129-140.  (Updated  from Table originally published in 12). 
 
Pregnancy  
Occasional patients have presented during pregnancy or post partum with sudden 
desaturation due to PAVM growth 94, 96, 97, 114, 115.  Of particular concern however, is the 
enhanced risk of PAVM haemorrhage 2, 11, 94, 96, 142-145, which may be fatal 11, 97. 
Thrombotic complications also occur in PAVM pregnancies, as in the general population 
in which pulmonary emboli are one of the commonest causes of maternal death 146. There 
was no reported difference in miscarriage rates in a retrospective study of 40 HHT patients 
compared to 80 controls 147. Normal pregnancy and delivery of a normal baby can occur in 
the presence of severe arterial hypoxaemia 116. 
 
The rates and types of major complications of PAVMs in pregnancy were examined in a 
cohort of 484 pregnancies 11.  The predominantly retrospective analyses demonstrated that 
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1.0% (95% confidence intervals 0.1, 1.9%) of pregnancies resulted in a major PAVM 
bleed (haemoptysis or haemothorax). Emergency interventions for PAVM haemorrhage 
included embolization, surgical resection, and induced delivery. One death was attributed 
to paradoxical emboli causing a myocardial infarction 11.  Overall, in 484 pregnancies in 
HHT/PAVM patients, 1.0% (0.13 1.9%) of pregnancies resulted in maternal death 11, with 
all maternal deaths occurring in women previously considered well.   In women 
experiencing a life-threatening event, prior awareness of HHT or PAVM diagnosis was 
associated with improved survival (p=0.041, Fisher's  test) 11.      
 
No means of distinguishing a group more likely to have significant pregnancy-related 
complications was identified 11: The severity of PAVMs associated with life-threatening 
PAVM haemorrhage could be evaluated in four women, only one of whom had low 
SaO2/markedly raised R-L shunts, and none of whom had evidence of pulmonary 
hypertension 11.   
 
 
Diving and flying 
PAVMs may be diagnosed in patients following investigations for decompression illness 
121, 122, or in-flight complications.  Two cases of in-flight PAVM haemorrhage (one 
haemoptysis, one haemothorax) were reported recently 148, in addition to cases of  
ischaemic stroke 3, 124.   
 
Children 
PAVMs may present in childhood, with impaired exercise tolerance, dyspnoea, or 
neurological complications 3, 86, 91, but such presentations are rare.  The vast majority of 
children who will go on to have PAVMs in adult life have no symptoms in childhood. A 
small proportion present symptomatically at the time of peripubertal growth 1, but the 
majority remain asymptomatic, as for adults.   
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Diagnosis 
Overview 
Figure 5a represents the conventional investigative pathways for generic patients with 
significant respiratory symptoms such as dyspnoea, haemoptysis or chest pain: PAVMs are 
infrequently identified as causative pathology in such general population patients.   
 
High proportions of HHT/PAVM patients are undiagnosed at the time of their PAVM-
induced ischaemic stroke or cerebral abscess 3,149 , documented at 66.7% and 64.3% 
respectively in one UK series 3.  There is evidence that PAVM treatments not only improve 
oxygenation and physiological parameters 104, 108, 135, 136 but also reduce stroke rates 3.    
The relative safety of PAVM screening and treatment regimes, and high rate of PAVM 
detection in the asymptomatic HHT population, has therefore led to the widespread 
introduction and recommendations for PAVM screening and treatment programmes 74, 
with pre screening discussions recommended 44, 150.   
Common to all PAVM screening programmes are the policies of minimising the radiation 
burden in an often young population; having a sensitive screen to detect all clinically 
significant PAVMs; and concern to avoid missing any treatable PAVMs. Early screens 
were based upon chest radiographs, SaO2/ PaO2 and shunt quantitation by 100% oxygen  
breathing or 99mTc scans, until it was recognized that there are no cut-offs for these tests 
which allow adequate sensitivity to rule out very small PAVMs that are still of clinical 
significance (Table 2).  For more sensitive screening tests, the choice lies between 
thoracic CT and contrast echocardiography. Contrast echocardiography (CE) was 
recommended by the International Guidelines group as a first line screen 74 (Figure 5b), 
sparing individuals with negative studies from the radiation burden of thoracic CT scans.  
At other institutions such as our own, CE has not been used routinely as a first line screen 
due to resource implications given the majority of echocardiograms are positive, and 
patient preference for the rapid and cannula-free CT scan (Figure 5c).    
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Who to screen? 
The international guidelines recommend screening adults and children at the time of initial 
clinical evaluation for HHT 74, and where initial screening is negative, after puberty, after 
pregnancy, and within 5 years preceding planned pregnancy.   For adults, screening post 
puberty and post pregnancy may be sufficient as there are no reports of PAVMs 
developing subsequently, but due to the paucity of published evidence, recommendations 
are to rescreen every 5-10 years 74.  
Figure 5: Legend: Alternative pathways for PAVM diagnosis.  a) Usual pathway 
for symptomatic patients presenting to general respiratory services.  b) Pathway 
recommended by international patient guidelines using contrast echocardiography as 
first line screen 74.  c) 2011 HHTIC London standard pathway.   d) 2011 HHTIC 
London option for individuals requesting a first line echocardiogram. Pre 
echocardiography oxygen saturations and chest x-ray allows avoidance of contrast 
echo in patients who are significantly desaturated, and most likely to get symptoms 
(usually migraine /aura), after contrast echocardiography, because they will have 
masses of bubble emboli. (If symptoms occur, immediate 100% oxygen will get rid of 
the bubbles and symptoms quickly).
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For children, while appropriate investigation and management of symptomatic children is 
essential, the question of screening healthy children from HHT families is much more 
controversial.  The international guidelines did not provide a separate recommendation for 
children as opposed to adults 74.  As previously presented, 3  based on the paucity of 
evidence for childhood complications from silent PAVMs in previously healthy children, we 
do not see sufficient indication to conduct a formal PAVM screen before the time of peri-pubertal 
PAVM growth and maturation, and resolution of the ethical, familial and radiation issues that 
influence paediatric discussions 3, 75. Some centres may recommend clinical examination and pulse 
oxygen saturation measurement in children from HHT families, but this too awaits further evidence 
that PAVM complications occur in healthy, asymptomatic children. 
 
Screening Methods 
Impaired oxygenation 
Hypoxemia breathing room air is the simplest method for detecting PAVM R-L shunts.  The 
differential diagnosis is wide, although orthodeoxia may point towards the presence of lower 
lobe PAVMs.  In the past, 100% inspired oxygen rebreathing was considered the gold 
standard for non-invasive methods of measuring the shunt as a fraction of the cardiac output. 
There are several practical problems with this method which depends upon good patient 
technique; two sets of arterial blood gas sampling without contamination by air bubbles; 
careful calibration of the oxygen electrode for high PaO2; and inherent estimations that tend 
to underestimate shunt size 105.  
 
Radiology investigations  
Chest radiographs: The radiographic appearances of PAVMs range from normality 
(particularly if diffuse small telangiectasia are present, or when lower lobe lesions are 
obscured by the diaphragm on the PA projection), through prominent bronchovascular 
markings, to the classical rounded mass with visible feeding or draining vessels.  The 
sensitivity of plain radiographs varies widely according to both the size and distribution of 
PAVMs, and the reported screening intention: Prior to 2007, many screening programs only 
reported PAVMs with feeding artery diameters greater than 3 mm, since these were widely 
assumed to be the PAVMs of clinical significance:  Data presented in this era were that the 
chest radiograph was abnormal in 60 to 90% of instances.  It is anticipated that the 
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frequency of positive chest radiographs will fall further as smaller PAVMs are sought, in 
keeping with the recognition that these also cause neurological complications 3 156.  
 
 
Table 2: Comparison of early PAVM screening regimes  
 
Modality Number 
screened 
Population Threshold value Sensitivity^ 
% 
 
Specificity 
     %   
 
1–
Specificity 
%& 
PaO2 
(100%O2) 
Haitjema, 1995 151 
Lee, 2003 152 
 
Kjeldsen, 1999 153 
Lee, 2003 152 
 
36 
59 
 
24 
29 
 
HHT* 
HHT* 
 
HHT* 
post-embol# 
 
< 575 mmHg ‡ 
< 575 mmHg ‡ 
< 500 mmHg ‡ 
< 500 mmHg‡ 
< 500 mmHg‡ 
 
88 
95 
66 
100 
33 
 
75 
8 
64 
30 
85 
 
25 
92 
36 
70 
15 
SaO2 (erect) 
Kjeldsen, 1999 153 
Thompson,1999 154 
 
24 
66 
 
HHT* 
post-embol# 
 
≤ 96% 
≤ 96% 
≤ 95% 
 
71 
73 
61 
 
100 
35 
75 
 
0 
65 
25 
99mTc-MAA 
shunt 
Thompson, 1999 154 
 
66 
 
post-embol# 
 
> 3.5% 
> 5.0% 
 
87 
68 
 
61 
72 
 
39 
28 
Contrast echo 
Lee, 2003 152 
Nanthakumar,2001155 
 
28 
59 
 
post-embol# 
HHT* 
 
bubbles in left heart
bubbles in left heart
 
100 
94 
 
21 
67 
 
79 
33 
 
Comparison of early PAVM screening regimes: SaO2, arterial oxygen saturation; 
99mTc-MAA,99mtechnetium-labelled albumin macroaggregates; HHT, hereditary 
haemorrhagic telangiectasia; embol, embolisation.^ Positive likelihood; &, false positive 
Likelihood.  * prospective study of an HHT population; # small residual shunts or no 
shunts; ‡ 575 and 500 mmHg represent  R–L shunts of ~ 5% and 9% respectively.(First 
published in 109, reproduced with permission from the publisher). 
 
Thoracic CT scanning:  Spiral, or helical, computerized tomography (CT) beautifully 
demonstrates the angiographic anatomy of almost all PAVMs; the radiation burden has been 
substantially decreased, and the resolution improved, over the past several years by the use 
of newer multislice, multidetector CT, which limit x-ray exposure to a single short breath-
hold acquisition, and which allow elegant multiplanar and three dimensional reconstructions 
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of the data. In the small number of cases where there are difficulties with interpretation of 
structures that appear vascular, confirmation of R-L shunting may be helpful. 
MRI: To date, MR has been less effective than CT or pulmonary angiography because small 
PAVMs with rapid blood flow are not visualised  157. With meticulous technique, the 
majority of treatable lesions will be visualized and this imaging modality is being used by 
some centres for pre-embolization assessment and for post-embolization follow-up 158, 159. 
Radionuclide scanning:   Following intravenous injection of technetium-99m (99mTc)-
labelled albumin microspheres (7-25µm) or macroaggregates (10-80µm), the right-to-left 
shunt can be assessed by calculating the quantity of tracer reaching the systemic circulation 
compared to the total quantity received 105  106.   
 
Angiography: Pre embolization, spiral, or helical, computerized tomography (CT) images 
are sufficient to beautifully demonstrate the angiographic anatomy of almost all PAVMs to 
inform on subsequent embolization approaches.  Diagnostic angiograms are therefore very 
rarely required, and in our centre, are only performed at the same session as therapeutic 
embolization. 
 
Contrast echocardiography 
Compared to the previously discussed modalities, respiratory physicians are generally less 
familiar with contrast echocardiography, recommended by the international guidelines 
committee as the initial PAVM screening test 74. The test is therefore discussed in detail.   
 
Bubble contrast echocardiography relies on the normal 100% first pass clearance of a 
microbubble on passage through the alveolar capillaries as the gas diffuses rapidly out of the 
microbubble into the alveolus down the concentration gradient. Microbubbles seen in the 
left heart should therefore be the result of a right to left shunt - either cardiac (most 
commonly a patent foramen ovale, PFO 160, 161), or pulmonary. Typically, with an 
intrapulmonary shunt such as a PAVM, the number of bubbles in the left heart increases 
over a matter of seconds.  The entry of bubbles is not affected by the cardiac cycle or 
respiration, and though influenced slightly by a Valsalva manoeuvre, this is in a more subtle 
manner to the changes observed with a PFO.  Although PFOs are said to produce earlier 
opacification, shunting may not occur for many beats after the right heart opacifies, until the 
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moment when the patient takes a breath in, causing shunting across the PFO. Intrapulmonary 
shunt origin is certain if the bubble density is greater in the left heart than the right, often 
requiring 30-60 seconds recording. 
 
In the absence of a R-L shunt, small numbers of bubbles (~< 5/frame) may be seen despite 
having passed through the alveolar capillaries. Such “alveolar transit“ bubbles are smaller 
than the bubbles in the right heart because most of the gas has been removed, but they have 
not entirely collapsed.  Alveolar transit bubble numbers increase with repeated injection, 
either because some of the bubbles are left over from the earlier injections, or due to 
changes/damage to the delicate alveolar capillary interface because of the previous passage 
of bubbles through alveolar capillaries.  Alveolar transit increases as cardiac output 
increases, and during peak exercise, most people have bubbles detectable in the left heart on 
contrast echocardiogram (PW, personal observation). Intrapulmonary shunting is also 
demonstrated in a proportion of healthy subjects at rest (5/19 in 162;  7% of 100 controls166).   
 
CE consistently detects more intrapulmonary R-L shunting in HHT patients than any other 
PAVM screening modality, and early manuscripts demonstrating high sensitivity 77 and low 
risk 155, 163, were the reason for the guideline recommendation 74.   While false negatives 
have been reported 155, 164, the negative predictive value of a negative CE assessed in several 
specialised units  is of the order of 98% 164.     
 
Table 3: Summary of published graded contrast echo series in HHT: Data in all 
groups drawn from studies of 71-90”HHT all” 165-167, 92 HHT1 83, and 97 HHT2 83 
individuals.  Posture and exact timings differed between the studies that were conducted 
in four different specialised HHT centres, but all documented the presence of late shunts 
after at least 3 cardiac cycles.  b/f; bubbles per frame; LVO, left ventricular 
opacification  * in HHT2 83 
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Unfortunately, completely negative scans are not particularly common in HHT patients 
(Table 3). To attempt to reduce the proportion of screened patients requiring subsequent 
thoracic CT scans, shunts have been graded, based on the number of microbubbles 
appearing in the left ventricle on a single frame 163.   Table 3 delineates the data suggesting 
that Grade 1 and Grade O shunt patients may be spared a CT scan.  One prospective series 
of 105 patients suggested this might extend to a grade 2 shunt 164, but in other studies, Grade 
2 positive shunts were associated with PAVMs of a size amenable to embolisation 155 165.  
 
The variations of positive predicted values in these reports may include biological factors 
such as the variability between hospitals/centres in the local HHT genotypes and hence rates 
of large PAVMs seen.  It is also possible that there was a contribution from the variability in 
how the contrast echocardiography was performed: The articles referenced in Table 3 used 
slightly different methods of producing bubble contrast including use 83  and non use 165 166 
167 of blood in the syringes, and use of Gelofusine 167 which produces a similar appearance 
to bubble contrast on echocardiography, but is not removed on first pass through the lungs.  
In addition, patient posture, exact timings and other test parameters differed between the 
studies. Such variation in study methodology is important as adequate opacification of the 
right heart is essential to demonstrate bubbles appearing in the left heart, and the density of 
bubbles in the right heart can be altered by varying factors such as the volumes and ratios of 
air, saline and the patient’s blood used; the number of times the mixture is pushed back and 
forth through a 3-way tap; the size of the IV cannula used; how proximal the injection site is 
and its relationship to the level of the heart; the patient’s posture; anatomic problems such as 
delayed arrival in muscular men as a result of axillary vein compression by well developed 
pectoral muscles; autonomic tone; and heart rate.   
 
Even though the studies in Table 3 were performed by highly experienced dedicated PAVM 
contrast echocardiography centres in which these factors were standardised, positive 
predicted values varied.  Where less dedicated centres choose to use a negative or Grade 1 
contrast echocardiographic study to withhold a CT scan for an HHT patient undergoing 
screening for PAVMs, it is essential that they are confident there were not methodological 
reasons for a possible false negative.   
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PAVM Embolization 
Methods of embolization 
As described elsewhere 168, prophylactic intravenous antibiotics are administered in all cases 
(1g Vancomycin) one hour before the combined diagnostic and therapeutic procedure. The 
pulmonary artery pressure is measured in all individuals at the time of angiography. 
Selective right and/or left pulmonary digital subtraction arteriograms are then obtained via a 
femoral venous approach to document the anatomy of treatable lesions. In patients in whom 
previous CT has demonstrated unilateral PAVMs, that side only need be studied at the time 
of angiography.  Selective catheterization of the feeding vessel(s) to each treatable PAVM is 
then performed and once a suitable position has been achieved as distally as possible within 
the feeding vessel, embolization is performed with an Amplatzer vascular plug (AVP) (AGA 
Medical Corporation, Plymouth, Minnesota USA) or metallic coils of an appropriate size for 
the vessel being occluded.  Embolization is ideally performed at the neck of the 
malformation (i.e. at the site of the arteriovenous communication) in an attempt to avoid the 
occlusion of normal pulmonary artery branches and to reduce the risk of the development of 
a bronchial arterial collateral supply to the sac.  Additional feeding vessels to this, and other, 
PAVMs are treated in the same manner. 
 
Amplatzer vascular plugs are rapidly becoming the preferred agent for PAVM embolization 
as they have a number of important advantages over coils: 
 Distal occlusion of the feeding vessel to a PAVM at the neck of the venous sac, 
is often very difficult to achieve with metallic coils, particularly when the feeding 
vessel is large, because of the risk of coil migration through the sac into the systemic 
circulation with potentially disastrous complications.  This problem is overcome in 
most PAVMs by the AVP; the vascular sheath through which the plug is to be 
deployed can usually be placed at the neck of the PAVM and can, in some instances, 
be introduced into the venous sac itself.  The plug can then be introduced with the 
sheath in this position and deployed during sheath withdrawal. 
 A larger number of PAVMs can be embolized in a single session, because 
complete occlusion of large diameter feeding arteries (measuring up to 12mm in 
diameter) can be achieved with a single AVP in the majority of cases, instead of   the 
use of several metallic coils. 
 A shorter length of vessel is occluded, reducing the likelihood of occluding 
vessels supplying normal lung;  
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The duration of the embolization intervention is determined by the number and complexity 
of the malformations requiring embolization and patient tolerance to the procedure but, in 
general, each procedure lasts between 90 and 120 minutes.  Post operatively, patients lie 
semi-erect in bed for 4 hrs before mobilizing.  The majority of individuals treated at our 
institution remain in hospital overnight because of the long distance they have to travel 
home and we are able, therefore, to obtain post-embolization oxygen saturation data on the 
morning of discharge to document the immediate response to treatment.    Although 
unlikely, it is possible that thrombus on an embolic device, or within the venous sac of an 
embolized PAVM, will migrate in the post-embolization period; we consider it reasonable, 
therefore, to advise patients on discharge to avoid strenuous exercise for several days post-
procedure.  Those with residual PAVMs of a treatable size are readmitted at approximately 
three month intervals for further embolization until complete occlusion of all of these lesions 
has been achieved.  
 
Other embolization techniques such as packing the venous sac with coils or using an 
occlusion balloon catheter to reduce flow during vessel occlusion are now rarely necessary 
since the introduction of detachable coils and plugs.  Post-embolization, residual shunting 
through untreatable (< 2 mm diameter) arterial feeding vessels is common.  For example, in 
a series of 192 PAVM patients in whom feeding arteries less than 3 mm in diameter were 
embolized, 3 70% had residual disease, a finding supported by other studies 135, 152, 169. 
 
Results of embolization  
Embolisation series published to date provide clear evidence for regression of the PAVM 
sac 170,substantial improvement in oxygenation  for patients with pre-embolization 
hypoxaemia 104, 108, 135, 136, 171-173 and effective treatment of life-threatening haemorrhage 2 97 
174. A recent study demonstrated the clinical efficacy of embolization in improving 
stroke/abscess risk, 3 though strokes/abscesses do occur in some patients post-embolization 
due to small untreatable PAVMs. There is also evidence that  the prevalence of migraine is 
reduced 175 139.  Since intracardiac shunt closure also often improves migraine,  a current 
hypothesis is that such shunts allow migraine trigger substances, possibly vasoactive amines 
liberated in venous blood, to reach the brain by circumventing the alveolar capillaries where 
they would normally be destroyed on first-pass. 
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When all feeding arteries to a PAVM sac have been obliterated, the sac regresses, with clear 
evidence of improvement by 6 months in most cases.  However, if all feeding arteries have 
not been embolized, or if recanalization of occluded vessels occurs, the sac will fail to 
regress.   It is expected that the switch to the use of Amplatzer plugs 168, 176 will reduce the 
likelihood of post embolization recanalization156,177,170.   
 
Risks of Embolization 
In expert hands, the technique is efficacious, and complications are rare, though the 
procedure is not without risk. Successive series highlight a learning curve 1, 109, and smaller 
series have higher complication rates 128.  The most common complication is of transient 
pleurisy in up to 10% of patients, particularly those with peripheral PAVMs, and higher 
rates are seen for patients with diffuse PAVMs 90.  The mechanism for the pleurisy is 
unknown but it appears unrelated to pulmonary infarction 88, 104. Angina, due to transient air 
bubble emboli, has been reduced by technical advances in later series.  There are occasional 
reports of long term neurological complications following paradoxical emboli 178.   
 
Development of Systemic Arterial Supply:  The risk of massive haemoptysis from PAVM 
sacs that persist post-embolization and that acquire a systemic arterial collateral blood 
supply was first highlighted in a small series published in 1998, when haemoptysis was a 
frequent complication 128. In a further series, 13 of 32 patients demonstrated abnormally 
large arteries of bronchial, inferior phrenic, musculophrenic, internal mammary or 
intercostal origin, but none of these cases experienced haemoptysis 179.  Peri-procedural 
pulmonary infarction 179 is not a pre- requisite for development of systemic arterial feeders.  
As elegantly demonstrated using post mortem aortograms and subsequent microradiographs, 
pulmonary emboli are one of the pulmonary pathologies that stimulate pathological 
bronchial artery proliferation, resulting in the acquisition of hypertrophied, tortuous 
systemic to pulmonary collaterals, in which systemic arteries penetrate the pulmonary 
vascular media and intima 180. These pathological communications are anatomically distinct 
from the normal communications between terminal branches of the bronchial 
microcirculation and peripheral pulmonary artery branches 1, 180.  
 
Where aberrant systemic arterial supply to PAVMs exists but has not manifest by 
haemoptysis, it is not clear whether embolization therapy is warranted.  It is intriguing to 
recall that there is currently no explanation for the control of the systemic-pulmonary 
pressure drop in normal bronchopulmonary communications, since the internal longitudinal 
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muscle bundles present in so called Sperrarterien (blockading arteries)  181, 182 do not reflect 
sphincter function but are generated by stretching the vessel 183.   Where aberrant systemic 
arterial supply to PAVMs is present in the setting of haemoptysis, which may be massive, 
favoured treatment is by selective bronchial artery angiography 184, 185, discussed elsewhere 
1, 186. 
 
 
Effect of embolization on pulmonary artery pressure: PAVM embolization102, 171, 187, 188 and 
surgical resection 189 can elevate Ppa by removal of the PAVM low resistance pathway.  
However, in the majority of 35 patients with consecutive Ppa measurements, there was no 
evidence of a sustained or acute change in Ppa 108.  In half, embolization led to a fall in Ppa, 
attributed to a reduction in cardiac output 171.    PAVM patients clearly differ in their 
haemodynamic responses to embolization, and it has been suggested that deleterious rises 
may relate to underlying hepatic AVMs 108, 187, 190.  Temporary balloon occlusion of the 
PAVM before definitive embolization has been suggested in order to identify which patients 
are at risk of such an increase 187, 190 but where Ppa mean did rise following definitive 
embolization (by 22mmHg), this rise was not predicted by test balloon occlusion 108. 
 
 
Post embolization follow-up  
Following initially complete embolization or surgical resection, residual macroscopic 
disease may develop several months after treatment, following a period of vascular 
remodeling,  unmasking or apparently provoking the development of additional PAVMs or 
new pulmonary artery feeder vessels.  As a result, review of all patients and right-to-left 
shunt measurement after several months is generally recommended, and a series of 
treatments may be needed.  The international guidelines 74 recommend post embolization CT 
at 6-12 months.  At our institution we prefer to limit radiation exposure in this often young 
population:  Initial follow up is therefore with CXR and oxygen saturations, with CTs 
reserved for patients demonstrating new symptoms, deteriorating oxygen saturations, or 
failure to obliterate a PAVM sac which would have been predicted based on angiographic 
appearances.  Further follow up is recommended for post embolization patients 2-3 yearly, 
and patients with small untreated PAVMs , or CE positive patients 1-5 yearly 74.  
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Other treatment options for PAVMs:  
 
Surgery 
Embolization has generally supplanted surgical procedures, due to reduced periprocedural 
risks, parenchymal sparing in patients at risk of recurrent disease, and the documented 
benefits.  Although there are no randomised control trials comparing embolization and 
surgery, it is recognized that to perform such studies now would be unethical in view of the 
reported benefits of embolization and recognition that the vast majority of PAVM patients 
do not have disease suitable for surgery 191.   
 
Surgical resection of PAVMs may be useful however, in two settings.  The first is as an 
adjunctive therapy for highly selective cases where further embolization is not feasible (the 
commonest reason being that the feeding artery is too small (< 2 mm diameter), but 
PAVMs are sufficiently localized for thoracoscopic resection).  At our institution, we 
reserve elective surgical approaches for highly selected patients with ongoing ischaemic 
strokes, transient ischaemic attacks, or significant respiratory symptoms following 
maximal embolization. Secondly, in emergency situations, particularly associated with 
massive haemoptysis, lobectomy or pneumonectomy may be appropriate 192,11. 
  
Lung transplantation has been undertaken in a few patients with severe hypoxemia 
secondary to diffuse disease. 193, 194.  However, the natural history of such disease is more 
favourable than might be expected:  In a retrospective series of 36 patients with diffuse 
PAVMs for whom follow-up data were available for a mean of 8.5 years (range 0.12- 26 
yr), 24 of the 27 survivors were working or studying full time, whereas one of the deaths 
was transplantation-associated 90.  Three severely hypoxaemic PAVM patients in our clinic 
who elected not to proceed with lung transplantation after assessments at two different 
transplant centres have since remained stable over 15-19 years respectively, and one 
patient has had three successful pregnancies.  Thus the long-term complications of 
untreated PAVMs, are likely in most cases to be less than transplantation-associated 
morbidity and mortality. 
 
Dental:  
In an effort to reduce frequency of cerebral abscess, antibiotic prophylaxis was 
recommended before dental and surgical procedures for patients with PAVMs and HHT, 
based on the endocarditis paradigm.  The American Heart Association 195 and British NICE 
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guideline committee 196 have both stated that antibiotic prophylaxis is no longer required 
for most patients with structural heart disease.  PAVM/HHT patients did not fall into the 
groups considered by AHA/NICE however 197, and individually, are at ~100 fold higher 
risk than patients with structural heart disease 3.  There is also strengthened evidence for an 
association between periodontal microorganisms and cerebral  abscess 3. As a result 
antibiotic prophylaxis is still recommended for PAVM/HHT patients prior to dental 
procedures, in addition to measures to improve overall  dental hygiene 197. 
 
Thromboembolic risk management:  
In contrast to advice given to patients in earlier years, it is now recognised that there are 
settings in which anticoagulants (and/or antiplatelet agents) are required 74 in order to 
prevent major ischaemic or thromboembolic sequelae.  Prophylactic dose anticoagulation 
for example is required during high risk periods for venous thromboemboli (VTE)10, 
particularly for HHT patients hospitalized with pulmonary AVM-induced cerebral abscess 
10. Where VTEs occur, treatment dose heparin and warfarin can be given, though clinical 
decisions are often compounded by recognition of pre-existing anaemia or concern about 
visceral haemorrhages 65. For patients experiencing transient ischemic attacks or ischaemic 
strokes, we recommend that options such as cessation of hormonal and prothrombotic 
therapies, and conventional antiplatelet therapy 198, should be considered on a case-by-case 
basis, even if there is underlying HHT 10.  In our experience, anticoagulation is tolerated 
surprisingly well by many patients, but primary prevention strategies are difficult to justify. 
199. 
 
 
Pregnancy management: 
As a result of case reports and small series, HHT/PAVM specialist centres have 
recommended PAVM treatment before pregnancy for many years.  Radiation assessment 
studies indicated that embolization may be undertaken during pregnancy 200, and routine 
embolization in the later stages of pregnancy is performed in some centres where pre-
pregnancy treatment was not feasible 74.  Nevertheless, in view of the life threatening 
nature of the haemorrhages, and uncertainty about the rate at which such complications 
occurred, some PAVM patients were being advised to avoid pregnancy. 
 
Based on the data from the study of 484 pregnancies in 199 women with HHT and PAVMs 
demonstrating that that the majority were able to have a normal pregnancy,  but a small 
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proportion did experience life-threatening complications11, general recommendations for 
the management of women with HHT/PAVMs were developed11.  These included 
management as “high risk” pregnancies;  maternal education to consider haemoptysis of 
any degree or sudden severe dyspnoea as a medical emergency prompting urgent 
hospitalization; and specific obstetric, and obstetric anaesthetic issues discussed in detail 
elsewhere 11.  As described in 11, we recommend PAVM screening and treatment pre-
pregnancy, but during pregnancy, PAVM embolization is generally not offered unless the 
pregnant patient is experiencing haemoptysis. This is because of the low risk of PAVM-
associated complications, lack of evidence that PAVM embolization during pregnancy in 
women who have not experienced a complication reduces the risk of haemorrhage in the 
second and third trimester; and risks associated with PAVM embolization which involves 
ionizing radiation and, as for any intervention, the potential for inducing pre-term labour. 
 
 
Diving and HHT /PAVMs:   
The international guidelines recommend that patients who have a PAVM, or patients with 
HHT in whom PAVMs have not been excluded, should avoid diving lifelong 74.  In our 
experience, while many patients are happy to be informed they should not take up this 
sport,  being cautioned against diving is extremely difficult for active divers, and many 
others in the large group of HHT/PAVM patients who are highly active and sporty 110.   
For existing divers, restricting dive profiles or using breathing gas mixtures that avoid 
venous bubble liberation should overcome the risk of decompression illness in the presence 
of a right to left shunt. If there are no venous bubbles, the presence of a right to left shunt 
cannot increase the risk of decompression illness. Before undertaking diving, we therefore 
recommend that an individual with a R-L shunt, such as a PAVM, should be counselled by 
a physician with knowledge of diving medicine. 
 
 
Anti-angiogenesis strategies 
The authors are alarmed about information and enquiries that they are receiving from 
patients and physicians regarding possible anti-angiogenesis approaches for PAVMs.  
Interest has arisen as a result of a brief report of a patient whose hepatic AVMs initially 
responded to the humanized anti VEGF antibody Bevazicimub (Avastin) 201, and evidence 
of topical efficacy in the treatment of HHT nosebleeds.  Thalidomide has also been 
suggested for use in HHT-related haemorrhage, based on case reports 202, 203 and a very 
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small uncontrolled short series 51.  The authors are aware of further case reports, and 
ongoing trials of these agents in carefully selected consenting patients in major HHT 
centres for other aspects of HHT, but not of any data or ongoing trials for PAVMs.    
 
In our opinion, in the absence of any data for PAVMs, the major toxicities of the currently 
available systemic approaches 204-207, preclude any use in PAVM patients whose longevity 
and long-term exercise capacitance have always surprised their physicians (see 
transplantation section above).  There is of course, however, great excitement about the 
mechanistic insights and potential for future therapeutic developments, but lessons may be 
learned from the withdrawal of FDA approval for Bevazicimub in the setting of metastatic 
breast cancer, a disease with a far graver prognosis than PAVMs, because treatment was 
associated with considerable toxicity, without sufficient evidence of benefit 208.  
 
 
 
PULMONARY HYPERTENSION IN HHT 
 
Overview 
PH has been recognised in a number of HHT patients 9, 95, 102, 209-212.  As recently reviewed 
13, 108, and explored elsewhere in this monograph, two forms of PH predominate in HHT.  
Post-capillary pulmonary hypertension (PH) develops as a result of long-term increases in 
left atrial pressure accompanying elevated cardiac output states, particularly in the setting 
of hepatic AVMs.  In many cases, this PCPH is reversible if the causative hepatic AVMs 
are treated, with liver transplantation the current treatment of choice 74, 213.  In addition, 
pulmonary arterial hypertension, characterised by elevated intrinsic pulmonary vascular 
resistance with low pulmonary venous (wedge) pressures, occurs 9, 102, 214, and appears to 
be independent to other HHT vascular pathologies. Mixed pictures are also observed 108.   
 
 
Prevalence 
The overall prevalence of PH in HHT is low, as shown by catheter-based studies in a group 
of 143 PAVM/HHT patients undergoing PAVM embolization (Figure 6) 108  and  an 
echocardiographic study from a separate HHT population, where estimated systolic PAP 
were above the normal range in 9 (20.5%) 215. 
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Types of pulmonary hypertension 
In HHT, pulmonary hypertension occurs predominantly in HHT2 families 214, 216, 217.  In 
part this reflects the common pathogenic pathways mutated in HHT and PAH (see Figure 
3) 9, 79, 214, 218.  However, HHT2 patients are also at higher risk of post capillary pulmonary 
hypertension (PCPH), as hepatic AVMs, and severe disease due to hepatic AVMs, is more 
common than in HHT1 7982, 219. It is not clear that ENG missense polymorphisms reported 
in association with PAH are HHT-disease causing, and in a recent PAH-HHT series, all 
cases resulted from  ALK1 mutations 217.  Nevertheless, there is evidence from animal 
models to implicate endoglin mutations in the pathogenesis of pulmonary hypertension 220.  
 
 
Implications if co-existing PAVMs 
Generally the presence of HHT/PAVMs does not modify the sub-speciality management 
protocols for PH, except for the need to rule out hepatic AVMs that may be a potentially 
reversible cause of PCPH.  When PAH occurs within HHT2/ALK1 patients, it may have a 
worse prognosis than when due to BMPR2 mutations 217.   
 
In contrast, the presence of PH substantially modifies risk benefit considerations regarding 
treatment of PAVMs (Table 4).  The risk of paradoxical embolic stroke is substantially 
lower in individuals with higher Ppa 125, and symptomatic relief from dyspnoea should not 
be expected for patients with pulmonary hypertension and higher SaO2. We conclude that 
for patients with pre-existing severe pulmonary hypertension, the risks of pulmonary AVM 
embolization generally outweigh potential benefits. However, the most difficult 
Figure 6: Ppa mean distribution in a 
UK PAVM series:   Comparison of Ppa 
mean for 143 patients PAVM patients 
undergoing embolization (plain 
symbols), and the four patients not 
offered embolization (ringed symbols).  
Reproduced from reference 125 (ERJ). 
Ppa mean exceeded 20mmHg in 9/143 
(6%), but only two patients referred 
from services other than specialised 
pulmonary hypertension units had Ppa 
mean exceeding 35mmHg. 
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judgements relate to individuals with severe PH and major haemoptysis or haemothorax 
which may be a terminal event 108.  In pregnant women (without PH) in our series 11, and in 
PH cases known to us, there was time for emergency intervention to be performed after the 
onset of herald symptoms. In such an emergency setting, patients and their physicians may 
consider the risks of precipitating a further, potentially fatal increase in Ppa justifiable.    
 
 
 
 
PAVM Risk     All PAVM  Pulmonary hypertension  References 
     patients   PAVM patients   
 
Ischaemic stroke         11.3%   lower (HR 0.89 (95% CI 0.83, 0.95)  
    per mmHg increase, p=6.2x105)          3   
 
Brain abscess               9%   Unchanged           3   
 
Dyspnoea   1.5; 3.2; 14; 37%    Universal, and more severe   
 
Haemoptysis  <10%; usually minor ? more common and severe       190 
 
Migraine   two fold excess  No data           137   
 
Growth    generally nil/slow ? increased           95 
 
Table 4: : PAVM risk-benefit analyses in the presence of pulmonary 
hypertension. Reproduced  from 125.  according to SaO2 quartiles (>96; 93-96; 88-
93; <88)% of population reported in 3, 108.except during puberty and pregnancy.  HR 
hazard ratio; CI confidence intervals. 
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Conclusions 
In summary, due to the risks of paradoxical embolic stroke and pregnancy-related 
complications, irrespective of symptoms, PAVM patients should be offered embolisation 
of all vessels of a size amenable to this form of treatment unless there are 
contraindications. They should also be provided with regular follow-up and advice on 
dental hygiene, antibiotic prophylaxis, pregnancy and diving. The importance of magnetic 
resonance imaging to rule out cerebral abscess for PAVM patients presenting with stroke-
like symptoms needs to be recognised. Pulmonary hypertension and/or hepatic AVMs 
with high output cardiac states are relative contraindications to embolisation in the non-
emergency situation. Surgery is rarely necessary and should be avoided if possible 
because of the likelihood of extensive or recurrent disease. There is no current role for 
anti-angiogenesis strategies. 
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